Affiliation:
1. Pfizer Central Research, Groton, CT 06340, USA
Abstract
Abstract:
In 1982, Takeda Inc. reported the discovery of ciglitazone (5-[4-(l methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione, ADD-3878), a compound which lowers blood glucose in animal models of Non Insulin Dependent Diabetes without an increase in insulin release, and which does not have an effect on the glycemia in normal animals. Since then many analogs have been produced, including troglitazone, pioglitazone, englitazone and darglitazone, and compounds where the thiazolidinedione ring has been replaced by other acidic moieties. Pharmacological studies have revealed effects on gluconeogenesis, glucose transport and glucose transporter expression, and a putative receptor in fat cells, PPARy, has been proposed. Clinical studies
on troglitazone and darglitazone have shown these compounds to have glucose lowering effects, as well as effects on insulin sensitivity, lipid levels and blood pressure.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献